AI-Designed Drugs Advance into Late-Stage Clinical Trials

AI-designed drugs are reaching late-stage clinical development, with Generate Biomedicines' GB-0895 and Enveda's ENV-294 in Phase IIa and rentosertib starting Phase III recruitment.

2026-10-08 ~ 2026-10-09 · 2 related posts

• AI-designed drugs reach late-stage trials as Insilico's rentosertib recruits Phase 3 — nathanbenaich · 2026-10-08
• AI-designed drugs reach late-stage trials: GB-0895, ENV-294 in Phase IIa, rentosertib recruiting Phase III — FinanceYF5 · 2026-10-09